A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Latest Information Update: 27 Apr 2023
At a glance
- Drugs V 01 Livzon Mabpharm/Institute of Biophysics, Chinese Academy of Sciences (Primary) ; BBIBP CorV; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Livzon Pharmaceuticals
- 22 Apr 2023 Status changed from active, no longer recruiting to completed.
- 31 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2022 According to a Livzon Pharmaceuticals media release, interim master data analysis has been completed.